Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Россия

statin and ezetimibe combination therapy; statin monotherapy

Retrospective Observational Study of the Efficacy and Safety of Statin Monotherapy or Statins in Combination With Ezetimibe in Patients Receiving Lipid-lowering Therapy in Both Primary and Secondary Prevention of CVD

Номер протоколаEZE-01/21
ФазаФаза не указана
Участников по плану — во всех странах исследования1 000
Сроки23.06.2021 — 08.07.2022
Начало: 23 июня 2021Окончание: 8 июля 2022
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04895098/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 1000 чел. во всех странах исследования.
  • Центров в реестре: 31 в 20 городах. Список — ниже на странице.
  • Плановая дата окончания (07.2022) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 8

Критерии включения

  • Patient can be included in the study only once.
  • Age > 18 years.
  • Patient receiving lipid-lowering therapy with statin monotherapy or statins in combination with ezetimibe for both primary and secondary prevention of CVD.
  • Receiving statins as monotherapy or statins in combination with ezetimibe in a stable dosing regimen for 3 or more months at the time of enrolment in the study.
  • Willingness and ability to sign an informed consent to participate in the study.
  • Availability of primary medical documentation, which allows assessment of all parameters necessary for the study from the moment of initiation of statin monotherapy or statins in combination with ezetimibe.
  • Initiation of lipid-lowering therapy not earlier than 2 years before enrolment into the study.

Критерии невключения

  • Age < 18 years.
  • A diagnosis of familial hypercholesterolemia made prior to study enrolment or the investigator's suspicious of the possible presence of familial hypercholesterolemia.
  • Change in lipid-lowering therapy within 3 months prior to study enrolment.
  • Concomitant administration of omega-3 PUFA with statin monotherapy or combination therapy of statins and ezetimibe, as well as the use of any methods of extracorporeal filtration and/or plasmapheresis.
  • Clinically significant impairment of liver and/or kidney function, which may impede interpretation of test results
  • Presence of hypothyroidism
  • Ezetimibe monotherapy
  • Intolerance to statins at any dose

Источник: ClinicalTrials.gov, NCT04895098 · запись обновлена в реестре 12 января 2023.

Дизайн и результаты

ДизайнНаблюдательное
Включено участников (факт, все страны)1 000
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (9)
  • Frequency of achieving target LDL (%) — at the time of enrolment in the study
  • Average change in LDL (absolute difference) — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • Average change in LDL (% from the baseline) — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • Average change in total cholesterol (% and absolute difference) — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • Average change in LDL (% and absolute difference) — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • Average change in TG (% and absolute difference) — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • The incidence of liver damage — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • The frequency of development of muscle damage — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study
  • Major adverse cardiovascular events (MACE) incidence — from the moment of initiation of lipid-lowering drug therapy (not earlier than 2 years before enrolment into the study) to inclusion in the study

Цель исследования

Retrospective observational study of the efficacy and safety of statin monotherapy or statins in combination with ezetimibe in patients receiving lipid-lowering therapy in both primary and secondary prevention of cardiovascular diseases (CVD). The study will include patients receiving lipid-lowering therapy in both primary and secondary prevention of CVD who have received therapy of interest for ≥ 3 months in the 2 years preceding the signing of informed consent, i.e. statins as monotherapy or in combination with ezetimibe in a stable mode (without dose adjustment and/or statin replacement). Effectiveness of therapy will be evaluated based on the data on changes in baseline levels of total cholesterol (CS), low density lipoproteins (LDL), high density lipoproteins (HDL), triglycerides (TG), data on which will be obtained from primary medical records. Demographic and anthropometric data on patients, information on the history of hyperlipidemia and concomitant diseases will also be obtained. Also, the study will collect data on the development of adverse reactions of particular interest during therapy (liver/muscle damage, major cardiovascular events (MACE).

Где проходит

31 центр в 20 городах
Иркутск
Казань
Кемерово
Краснодар
Новосибирск
Омск
Петрозаводск

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04895098 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.